All funding news

Biotech — funding news

23 recent Biotech rounds across our tracked sources.

Zumutor Biologics logo
🇺🇸Zumutor BiologicsImmunotherapy

Zumutor develops NK cell checkpoint immunotherapies to enhance natural killer cell activity against tumors.

$7.3MSeries B
Investor undisclosed
A $7.3M Series B for NK cell immunotherapy signals that checkpoint modulation (beyond the saturated PD-1/PD-L1 space) is attracting serious capital—especially with Accel backing, which rarely touches biotech unless the science is differentiated. They're likely funding IND-enabling studies and early clinical work, which means the NK cell thesis has moved past pure R&D into validation. If you're building in adjacent cell therapy or checkpoint biology, this validates that investors are willing to fund the harder immunology problems when the mechanism is genuinely novel.
Kardigan logo
🇺🇸KardiganCardiology

Kardigan develops cardiovascular therapeutics to treat heart disease.

UndisclosedIPO
Investor undisclosed
Fesarius Therapeutics logo
Fesarius TherapeuticsTherapeutics

Fesarius Therapeutics develops novel therapeutic treatments targeting unmet medical needs in disease areas.

$20MSeries A
Investor undisclosed
A $20M Series A for an early-stage biotech with vague positioning and undisclosed backers is a yellow flag—either the company is genuinely early-stage (pre-clinical or single-target) or the round details are being kept quiet for IP reasons. If you're building in adjacent biotech spaces, watch whether Fesarius publishes data in the next 12-18 months; silent fundraising often means either a pivot or a long runway before proof-of-concept, which affects how you think about your own validation timeline.
B
🇨🇳Batai MedicalBiotech

Batai Medical develops biotech solutions for the Chinese healthcare market.

$280KSeries D
Investor undisclosed
A $300K Series D in 2026 is a red flag—either this is a down round or the company is in serious trouble. If Batai is still fundraising at this stage with this amount, it suggests the China biotech market is either consolidating hard or this company lost momentum with earlier backers. If you're building biotech in Asia, watch whether Chinese VCs are rotating away from early-stage biotech entirely.
巴
🇨🇳

巴泰医疗

Medical Devices

Batai Medical develops innovative medical devices for clinical diagnostics and patient monitoring in China.

$28MSeries D
Investor undisclosed
A $28M Series D for a Chinese diagnostic device company signals that domestic medtech is moving past import-substitution into actual innovation—investors are still backing hardware plays in China despite global skepticism. At this stage, the capital likely funds manufacturing scale-up and clinical validation for regulatory approval, not R&D. If you're building in adjacent diagnostics or monitoring, watch whether Batai pursues direct-to-hospital sales or DTC channels; that playbook will tell you how much pricing power Chinese medtech actually has versus Western incumbents.
I
🇮🇳Immuneel TherapeuticsGene Therapy

Immuneel Therapeutics develops affordable CAR-T cell therapies for blood cancers including lymphoma and leukemia.

$1Series B
S
Singularity AMC
RKE
+1
百
🇨🇳

百奥几何

Life Sciences Software

百奥几何 builds microscopic world models to accelerate life sciences research and drug discovery.

UndisclosedStrategic
Investor undisclosed
百
🇨🇳

百曜科技

Biotech AI

百曜科技 builds AI-powered virtual cell simulations for biotech research and drug discovery.

Undisclosed
Investor undisclosed
微光医疗 logo
🇨🇳

微光医疗

Medical Devices

微光医疗 develops medical imaging and diagnostic devices for clinical applications.

Undisclosed
Investor undisclosed
I
🇨🇳iRegene TherapeuticsCell TherapyVerified

iRegene Therapeutics builds an AI-powered cell therapy platform using chemical induction to generate functional cells for age-related diseases like Parkinson's and vision impairment.

$294KSeries C1
G
Guanghe Capital
X
A $300K Series C1 in 2026 suggests iRegene is either pre-revenue or early-traction with Chinese domestic investors—this is survival/runway funding, not growth capital. If you're building biotech infrastructure (assays, manufacturing, regulatory consulting), watch that China is still funding cell therapy despite Western caution on timelines; the real signal is whether they can move from chemical induction to clinical validation without needing $50M+ Series D.
睿
🇨🇳

睿健医药

Pharmaceuticals

睿健医药 develops pharmaceutical treatments for unmet medical needs in China.

$29.4MSeries C1
Investor undisclosed
A $29.4M Series C1 for a China-focused biotech signals that domestic pharma funding is still flowing despite macro headwinds—but the round size suggests investors are being selective about clinical-stage assets with real unmet need angles rather than me-too plays. If you're building in adjacent biotech spaces (diagnostics, CRO services, drug delivery), this shows there's still capital for companies solving actual problems in China's healthcare system, just with higher bar for differentiation than 2-3 years ago.
Triomics logo
🇺🇸TriomicsOncology AI

Triomics builds AI software for oncology practices to automate clinical trial matching, appointment prep, and chart summarization.

$22MSeries B
Battery Ventures logo
Battery Ventures
NLightspeed logoY Combinator logo
A $22M Series B for oncology workflow automation signals that VCs are betting on AI-as-glue for fragmented clinical systems—not just diagnosis. Triomics is likely using this to expand from trial matching into the full patient journey (EHR integration, insurance pre-auth, follow-up scheduling). If you're building in adjacent healthcare verticals (rheumatology, cardiology), watch whether they're hiring for horizontal platform plays or staying vertical-focused; that tells you if the TAM is really about oncology or about replacing the broken appointment/documentation layer everywhere.
水
🇨🇳

水赋能电子科技

Hydrogen Health

水赋能电子科技 develops hydrogen health technology products for wellness consumers seeking alternative health solutions.

$9.8MAngel
Investor undisclosed
A $9.8M angel round for hydrogen wellness tech in China signals serious capital appetite for alternative health categories in Asia—this isn't a typical biotech play but consumer hardware/supplements with biotech framing. If you're building in adjacent wellness verticals (longevity, biohacking, functional beverages), watch whether this company hits distribution through e-commerce or medical channels; that path determines if the category scales or stays niche.
星
🇨🇳

星曜坤泽

Innovative Drugs

星曜坤泽 develops innovative therapeutics for hepatic diseases.

$58.0MSeries B
Investor undisclosed
A $58M Series B for a China-based hepatic disease biotech signals that deep-pocketed domestic players like Fosun Pharma are still backing clinical-stage drug candidates despite global biotech funding headwinds—this round likely funds Phase 2/3 trials and regulatory pathway work. If you're building in adjacent therapeutic areas (GI, metabolic disease), watch whether Chinese biotech can compress timelines and costs enough to compete on efficacy rather than just price; that playbook matters for your own unit economics.
Patina logo
🇺🇸PatinaFragrance Tech

Patina builds AI-designed fragrance molecules for perfumers using machine learning and a biological smell foundation model.

$2MSeed
Investor undisclosed
A $2M seed for AI fragrance design signals that biotech investors are now comfortable betting on narrow, high-margin verticals where ML can compress R&D cycles—this isn't about scale, it's about replacing expensive chemist time. If you're in materials science, synthetic biology, or any field where domain experts currently do expensive iterative design work, watch how Patina's go-to-market unfolds; the playbook of embedding AI into professional workflows (not replacing the professional) is becoming repeatable.
Imperagen logo
🇬🇧ImperagenEnzyme EngineeringVerified

Imperagen uses quantum simulation and AI to engineer enzymes faster and cheaper than traditional methods.

$6.3MSeed
P
PXN Ventures
IN
A $6.3M seed for computational biotech signals that VCs are betting on simulation-first drug discovery—the bet is that quantum + AI can compress years of wet-lab iteration into months. If you're building in adjacent biotech infrastructure (ADME prediction, protein folding, synthetic biology tooling), this validates that computational de-risking is fundable before you have clinical data; the capital is flowing to founders who can show computational shortcuts to expensive experiments.
VITL logo
🇺🇸VITLHealthcare Software

VITL connects cash-pay clinics to compounding pharmacies with real-time pricing and e-prescribing.

$7.5MSeries A
S
SignalFire
VITL's $7.5M Series A signals that the cash-pay clinic ecosystem is mature enough to support infrastructure plays—these clinics need operational plumbing as much as patient volume. If you're building in adjacent healthcare workflows (telehealth, direct-to-consumer pharma, specialty RX), this shows there's real willingness to pay for integration layers that reduce friction between fragmented providers.
Blank Bio logo
🇺🇸Blank BioBiotech

Blank Bio develops cell engineering technology to create therapeutic cells for treating diseases.

$7.2MSeed
Investor undisclosed
A $7.2M seed for cell engineering suggests investors are betting on the tooling layer, not just one-off therapies—this is about making cell manufacturing repeatable and cheaper. If you're in adjacent biotech (gene therapy, immunotherapy platforms), watch whether Blank Bio's approach becomes the standard for de-risking cell line development, because that directly affects your manufacturing timeline and unit economics.
Musely logo
🇺🇸MuselyTelemedicine

Musely delivers personalized compounded treatments for skin, hair, and menopause via asynchronous telemedicine consultations with specialists.

$360MStrategic
General Catalyst logo
General Catalyst
A $360M strategic round for a telemedicine + compounding play signals that personalized medicine at scale is finally hitting unit economics that matter to large investors—this isn't about novelty anymore, it's about defensible margins on repeat prescriptions. If you're building in adjacent health verticals (mental health, GI, dermatology), watch how Musely uses this capital: likely expanding specialist network, manufacturing capacity, and insurance reimbursement infrastructure, which are the actual moats in this space, not the app.
MiRus logo
🇺🇸MiRusMedical Devices

MiRus develops innovative cardiac medical devices for heart-valve treatment and repair.

$1.5BStrategic
B
Boston Scientific
Boston Scientific dropping $1.5B on a cardiac device company signals they're betting structural heart repair (especially valve work) is moving from niche to volume—likely because minimally invasive techniques are finally hitting adoption curves that justify acquisition-scale bets. If you're in adjacent med-tech (neurotech, orthopedic devices, anything procedural), watch how MiRus uses this capital: it'll probably go to clinical validation and manufacturing scale, not R&D, which means the category is past proof-of-concept and into 'can we make this routine.'
Degron Therapeutics logo
🇺🇸Degron TherapeuticsTherapeutics
$40MSeries A Extension
Investor undisclosed
A $40M Series A extension in May 2026 signals that Degron's protein degradation platform cleared a meaningful clinical or technical milestone—likely IND-enabling data or early efficacy readout—without needing a full Series B repricing. This is the biotech equivalent of a founder getting a bridge to prove out the next phase before a bigger round. If you're building in adjacent modalities (PROTACs, molecular glue, E3 ligase engineering), watch whether Degron's next 18 months show clinical traction; if they do, it validates that degradation-based approaches are moving from platform hype to real drug candidates, which changes investor appetite for your space.
Immunocan logo
🇨🇳ImmunocanAntibody Discovery

Antibody discovery platform using gene-editing technologies with multi-species platforms (mouse, alpaca, rabbit) and AI-driven antibody drug screening.

$35MSeries A
V
Vivo Capital
GKT
A $35M Series A for antibody discovery in China signals that non-US biotech platforms are now raising at scale—this isn't a regional play anymore. The multi-species + AI angle suggests the market is moving past single-platform discovery; if you're building biotech tooling (CDMO, protein engineering, screening automation), watch whether Chinese platforms start undercutting Western incumbents on cost while matching quality. The Vivo Capital lead also matters: they back deep-tech infrastructure, so this validates that antibody discovery is now seen as foundational plumbing, not a one-off service.